FDA approval for CR Bard's collagen haemostat:
This article was originally published in Clinica
Executive Summary
CR Bard's subsidiary Davol has received US FDA approval to market its Avitene Ultrafoam collagen haemostat, a collagen sponge designed to stop bleeding during surgical procedures by accelerating blood clot formation. Its uses include neurosurgery where topical haemostats are most frequently used. The sponge provides surgeons with better visibility during a surgical procedure by minimising the collection of blood, minimises the patients blood loss and prevents post-operative complications due to haemorrhage, said the Murray Hill, New Jersey-based company.